$1.50
arrow_drop_down1.31%Key Stats | |
---|---|
Open | $1.52 |
Prev. Close | $1.52 |
EPS | -0.96 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $78.56M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.48 | 1.54 |
52 Week Range | 1.17 | 6.87 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -0.96 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway